Complement activation and endotoxin levels in systemic meningococcal disease
- PMID: 2471750
- DOI: 10.1093/infdis/160.1.58
Complement activation and endotoxin levels in systemic meningococcal disease
Abstract
The activation state of the complement system in 39 consecutively admitted patients with systemic meningococcal disease was studied prospectively using two monoclonal antibodies reacting with neoepitopes exposed during complement activation. The fluid-phase C3 activation products and SC5b-9 (terminal complement complex) were strongly correlated to the levels of endotoxin (lipooligosaccharides, LOS) in plasma on admission (r = .79, P less than .0001 and r = .76, P less than .0001, respectively) and to fatality. Maximum complement activation in survivors occurred 7h (median; range 0-44 h) after initiation of antibiotic treatment. The most severely ill patients had the capacity to activate the whole complement cascade. In nonsurvivors, high-grade activation often continued until the patients died. The results suggest that LOS are important activators of complement in systemic meningococcal disease and that complement-activating products, in concert with other mediators, may contribute to the multiple organ failure and death occurring in the most severe cases.
Similar articles
-
The quantitative association of plasma endotoxin, antithrombin, protein C, extrinsic pathway inhibitor and fibrinopeptide A in systemic meningococcal disease.Thromb Res. 1989 Aug 15;55(4):459-70. doi: 10.1016/0049-3848(89)90054-6. Thromb Res. 1989. PMID: 2510354
-
Magnitude of bacteremia and complement activation during Neisseria meningitidis infection: study of two co-primary cases with different clinical presentations.Eur J Clin Microbiol. 1984 Oct;3(5):439-41. doi: 10.1007/BF02017367. Eur J Clin Microbiol. 1984. PMID: 6437810
-
Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease.J Infect Dis. 1989 Feb;159(2):195-204. doi: 10.1093/infdis/159.2.195. J Infect Dis. 1989. PMID: 2492587
-
Pathophysiology of meningococcal sepsis in children.Eur J Pediatr. 1998 Nov;157(11):869-80. doi: 10.1007/s004310050958. Eur J Pediatr. 1998. PMID: 9835428 Review.
-
Interactions between Neisseria meningitidis and the complement system.Trends Microbiol. 2007 May;15(5):233-40. doi: 10.1016/j.tim.2007.03.005. Epub 2007 Mar 29. Trends Microbiol. 2007. PMID: 17398100 Review.
Cited by
-
Minimal oligosaccharide structures required for induction of immune responses against meningococcal immunotype L1, L2, and L3,7,9 lipopolysaccharides determined by using synthetic oligosaccharide-protein conjugates.Infect Immun. 1991 Oct;59(10):3566-73. doi: 10.1128/iai.59.10.3566-3573.1991. Infect Immun. 1991. PMID: 1910006 Free PMC article.
-
Complement deficiencies and meningococcal disease.Clin Exp Immunol. 1991 Oct;86 Suppl 1(Suppl 1):57-62. doi: 10.1111/j.1365-2249.1991.tb06209.x. Clin Exp Immunol. 1991. PMID: 1934605 Free PMC article. Review. No abstract available.
-
Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia.Clin Exp Immunol. 2004 Jan;135(1):114-8. doi: 10.1111/j.1365-2249.2004.02315.x. Clin Exp Immunol. 2004. PMID: 14678271 Free PMC article. Clinical Trial.
-
Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome.Pediatr Nephrol. 2017 Feb;32(2):297-309. doi: 10.1007/s00467-016-3496-0. Epub 2016 Oct 7. Pediatr Nephrol. 2017. PMID: 27718086 Free PMC article.
-
Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.Mol Immunol. 2011 Sep;48(15-16):2159-69. doi: 10.1016/j.molimm.2011.07.011. Epub 2011 Aug 11. Mol Immunol. 2011. PMID: 21839519 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous